摘要
目的 探究华蟾素联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效。方法 选取2019年3月至2022年3月浙江省荣军医院收治的70例非小细胞肺癌患者,随机分为联合组(n=35,华蟾素联合多西紫杉醇+顺铂化疗),对照组(n=35,多西紫杉醇+顺铂化疗)。用ELISA测定血管内皮生长因子(VEGF)、癌胚抗原(CEA)、细胞角蛋白19(CK19)、糖类抗原125(CA125)水平;用卡氏状态(KPS)评分评估患者的生活质量;比较两组不良反应情况。结果 联合组疾病控制率(33/35,94.29%)高于对照组(25/35,71.43%)(P<0.05)。治疗后,两组患者VEGF水平均降低,KPS评分均升高(P<0.05),联合组更佳(P<0.05)。治疗后,对照组和联合组患者血清CEA、CA125和CK19水平明显低于治疗前(P<0.05),联合组低于对照组(P<0.05)。联合组不良反应发生率(5/35,14.29%)低于对照组(13/35,37.14%)(P<0.05)。结论 华蟾素联合多西紫杉醇+顺铂化疗治疗非小细胞肺癌的效果较好,使肿瘤标志物以及VEGF水平下降并且安全性较高。
Objective To investigate the impacts of cinobufotalin combined with docetaxel+cisplatin chemotherapy on the disease control and the level of vascular endothelial growth factor(VEGF)in serum of patients with non-small cell lung cancer.Methods Totally 70 patients with non-small cell lung cancer admitted to Zhejiang Veteran Hospital from March 2019 to March 2022 were included.They were randomly divided into combination group(cinobufotalin combined with docetaxel+cisplatin,n=35)and control group(docetaxel+cisplatin chemotherapy alone,n=35).The disease control rates of two groups,serum VEGF level,carcinoembryonic antigen(CEA),cytokeratin 19(CK19)and carbohydrate antigen 125(CA125)were measured using ELISA;life quality of patients was evaluated with the KPS score;The adverse events between two groups were compared.Results The disease control rate in the combination group(33/35,94.29%)was higher than that that of control group(25/35,71.43%,)(P<0.05).After treatment,the level of VEGF in both groups of patients decreased,and the KPS score increased(P<0.05)especially in the combination group(P<0.05).After treatment,the level of serum CEA,CA125,and CK19 of control group and combination group were obviously lower than those before treatment(P<0.05),while those in the combination group were even lower(P<0.05).The incidence of adverse events in the combination group(5/35,14.29%)was lower than that in the control group(13/35,37.14%)(P<0.05).Conclusions Cinobufotalin combined with docetaxel+cisplatin chemotherapy as a potential new chemotherapy significantly reduces the level of VEGF and tumor biomarkers in serum factor,improves the life quality of patients.The combined therapy is proved tobe safe.
作者
李娟
李晓峰
徐生志
唐凯
LI Juan;LI Xiaofeng;XU Shengzhi;TANG Kai(Department of Gastroenterology and Oncology,Zhejiang Veteran Hospital,Jiaxing 341001,China;Chest Disease Diagnosis and Treatment Center,Zhejiang Veteran Hospital,Jiaxing 341001,China)
出处
《基础医学与临床》
2024年第2期247-251,共5页
Basic and Clinical Medicine
基金
嘉兴市科技计划(2019AD32266)。
